Company Hosting Educational Program on OFF
Periods and Presenting Data at Upcoming 4th World Parkinson
Congress (WPC)
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced it
has launched a new community resource for people with Parkinson’s,
“The Many Faces of OFFSM1” Facebook page. The site, which is going
live in conjunction with the upcoming 4th World Parkinson Congress
(WPC), will provide a forum for people with Parkinson’s to learn
more about OFF periods and connect with each other to share
experiences.
This Smart News Release features an
interactive multimedia capsule. View the full release here:
http://www.businesswire.com/news/home/20160915005089/en/
(Graphic: Business Wire)
OFF periods are characterized by the re-emergence of Parkinson’s
symptoms, including motor symptoms such as the impaired ability to
move, muscle stiffness, and tremor.
“People with Parkinson’s regularly tell us that they need more
information about OFF periods and would also value an online forum
dedicated to the impact of OFF, as they don’t always have a
dialogue with their healthcare team about these experiences,” said
David Squillacote, M.D., Vice President, Medical Affairs for
Acorda. “We established this new resource to provide high-quality
content from the community and healthcare professionals, and to
enable discussions about OFF among people with Parkinson’s.”
“The Many Faces of OFF” Facebook page includes videos of people
with Parkinson’s and care partners talking about their personal
challenges of OFF. The page also provides explanations of key
concepts and tips for living with OFF periods, and is expected to
host Parkinson’s disease events. Importantly, the page encourages
the Parkinson’s community to participate and share their
stories.
Acorda is launching the Facebook page as part of a broader
educational initiative around OFF periods. At this year’s WPC,
being held September 20-23 in Portland, OR, Acorda is hosting a
symposium entitled “The Many Faces of OFF: Realities and Impact.”
This symposium will feature people with Parkinson’s discussing
their experience with OFF periods, while movement disorder
specialists Raj Pahwa, M.D. and Larry Elmer, M.D, Ph.D. will
discuss the impact of OFF, and challenges to effective
communication of this impact between people with Parkinson’s and
their physicians.
“The Many Faces of OFF” symposium is being held on September 22
at 7:00 pm and is open to all WPC attendees. Registration
information can be found here. Acorda will also host an interactive
experience about OFF periods at its “The Many Faces of OFF” booth
(WPC Booth #800).
Acorda is also presenting several research posters at WPC.
Approximately one million Americans, 1.2 million Europeans, and
between seven and ten million people worldwide suffer from
Parkinson's disease.
1 The Many Faces of OFF is a service mark of Acorda
Therapeutics, Inc.
About Parkinson’s Disease and OFF Periods
Parkinson's disease is a progressive neurodegenerative disorder
resulting from the gradual loss of certain neurons responsible for
producing dopamine, which causes impairment of motor function
including impaired ability to move, muscle stiffness and tremors.
Non-motor symptoms are also common; they include anxiety,
depression, sleep difficulties and gastrointestinal (GI) challenges
among others.
As Parkinson’s disease progresses, people with Parkinson’s
experience OFF periods, during which symptoms re-emerge. OFF
periods increase in frequency and severity during the course of the
disease.
In the United States, approximately 350,000 people with
Parkinson’s experience OFF periods. OFF periods are inadequately
addressed by available therapies and are considered one of the
greatest unmet medical needs facing people with Parkinson's
disease.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a
biotechnology company focused on developing therapies that restore
function and improve the lives of people with neurological
disorders.
For more information, please visit the Company’s website
at: www.acorda.com.
Forward-Looking Statement
This press release includes forward-looking statements. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects
should be considered forward-looking. These statements are subject
to risks and uncertainties that could cause actual results to
differ materially, including: the ability to complete the Biotie
transaction on a timely basis; the ability to realize the benefits
anticipated from the Biotie and Civitas transactions, among other
reasons because acquired development programs are generally subject
to all the risks inherent in the drug development process and our
knowledge of the risks specifically relevant to acquired programs
generally improves over time; the ability to successfully integrate
Biotie’s operations and Civitas’ operations, respectively, into our
operations; we may need to raise additional funds to finance our
expanded operations and may not be able to do so on acceptable
terms; our ability to successfully market and sell
Ampyra (dalfampridine) Extended Release Tablets, 10 mg in the
U.S.; third party payers (including governmental agencies) may not
reimburse for the use of Ampyra or our other products at acceptable
rates or at all and may impose restrictive prior authorization
requirements that limit or block prescriptions; the risk of
unfavorable results from future studies of Ampyra or from our other
research and development programs, including CVT-301 or any other
acquired or in-licensed programs; we may not be able to complete
development of, obtain regulatory approval for, or successfully
market CVT-301, any other products under development, or the
products that we will acquire when we complete the Biotie
transaction; the occurrence of adverse safety events with our
products; delays in obtaining or failure to obtain and maintain
regulatory approval of or to successfully market Fampyra outside of
the U.S. and our dependence on our collaborator Biogen in
connection therewith; competition; failure to protect our
intellectual property, to defend against the intellectual property
claims of others or to obtain third party intellectual property
licenses needed for the commercialization of our products; and
failure to comply with regulatory requirements could result in
adverse action by regulatory agencies.
These and other risks are described in greater detail in our
filings with the Securities and Exchange Commission. We may not
actually achieve the goals or plans described in our
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this presentation are made only as of the date hereof, and we
disclaim any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this presentation.
PD 5273
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160915005089/en/
Acorda TherapeuticsJeff Macdonald,
914-326-5232jmacdonald@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2023 to Apr 2024